Daniel is a lawyer in the firm’s Capital Markets & Securities department, specializing in providing advisory services to companies on legal issues relating to the capital market & securities and corporate law.
Daniel has experience in providing legal advice to investment funds, financial entities and public and private companies in relation to various aspects of corporate law and securities law, including IPOs and the subsequent offers of securities, public and private placements and tender offers. All this in addition to the on-going corporate and securities advice and representation of the firm’s clients before the Israeli Securities Authority and at the Tel-Aviv Stock Exchange Ltd.
Daniel provides legal advice to a wide range of funds, portfolio management, investment advisers, investment marketers and underwriters (including representing underwriters in public equity offerings in the NASDAQ).
Prior to joining our firm, Daniel worked at a law firm specializing in the capital market, investment funds and financial entities and served as a teaching assistant in a corporate law course at Sha’arei Mishpat Law School.
Daniel is a member of the high-tech committee of the Israel Bar Association and the capital markets and Business forum of the Israel Bar Association.
Sha’arei Mishpat Law School (LL.B., specializing in commercial law), 2013
Bar-Ilan University (LL.M., specializing in commercial law), 2014.
Member of Israel Bar Association since 2014
News and updates - Daniel Israeli:
Innovations in the Israeli Partnerships Legislation
In order to improve the Israeli partnership market and in order to bridge the wide gap that exists between partnership laws in Israel and the partnership laws in other countries, in December 2016, the Ministry of Justice published a draft Memorandum of Law – Partnerships.
Cellect Biotechnology Completed a Nasdaq IPO
On 31st July 2016 Cellect Biotechnology announced that it has completed its Nasdaq IPO, raising $8.4 million. Cellect Biotechnology will be traded on Nasdaq in parallel with its listing on the Tel Aviv Stock Exchange. Barnea & Co. represented a group of US underwriters, led by H.C. Wainwright & Co., LLC, in the process of submission by Cellect Biotechnology of a prospectus for the Nasdaq listing. Cellect Biotechnology develops innovative technologies in the stem cells sphere.
Further Concessions to Public Companies
A number of legislative amendments relating to the capital market have been promulgated recently, including